Developed countries could pay for hepatitis B vaccination in developing countriesBMJ 1998; 316 doi: https://doi.org/10.1136/bmj.316.7142.1457 (Published 09 May 1998) Cite this as: BMJ 1998;316:1457
- N J Gay, Principal scientist,
- W J Edmunds, Research fellow
- Immunisation Division, Public Health Laboratory Service Communicable Disease Surveillance Centre, London NW9 5EQ
- Department of Biological Sciences, University of Warwick, Coventry CV4 7AL
EDITOR—The debate about the most cost effective policy for vaccination against hepatitis B in the United Kingdom has centred on the relative merits of selective and universal vaccination. 1 2 A more imaginative approach is worth consideration.
The current incidence of acute hepatitis B in the United Kingdom suggests that the lifetime risk of acquiring infection is 0.4% (excepting perinatal transmission, which is controllable by well implemented antenatal screening) (Public Health Laboratory Service, unpublished paper). If 6% of infected people are assumed to develop chronic carriage, …